The 29th International Congress of the World Muscle Society (WMS) will be held from October 8 to 12, 2024 in Prague, Czech Republic. The Institute of Myology will be very well represented, with many scientific and clinical experts present to discuss clinical and fundamental research topics. Dr Andreea Seferian, clinician at I-Motion, will be presenting … Continued
On 29 and 30 November 2024, the Telethon will shine out across France to support the fight of families and researchers against rare diseases. Find out more about the ambassador families who will be speaking out on behalf of people with rare diseases, and about Mika, the patron of the event, and the ambassador towns … Continued
Following several proofs of concept, Atamyo Therapeutics, a spin-off from Geenethon, is to start a new gene therapy trial in patients suffering from limb-girdle muscular dystrophy (LGMD) R5 linked to SGCG (gamma-sarcoglycanopathy). Its aim is to test the safety, pharmacodynamics and efficacy of ATA-200, a product resulting from the work of Isabelle Richard, a researcher … Continued
After Matt Pokora, Soprano and Kev Adams, it’s singer and composer Vianney’s turn to join forces with researchers, families and thousands of volunteers across France in the fight against rare diseases on 8 and 9 December 2023. The ambassador families for the next Telethon reflect the victories won thanks to you, against diseases that were once incurable, and … Continued
The SAPPHIRE trial is an international, randomised, double-blind, placebo-controlled phase III trial that will evaluate the effects of a dual treatment : apitegromab (an anti-myostatin developed by Scholar Rock) injected intravenously every 4 weeks for one year, in addition to treatment with nusinersen or risdiplam, in non-walking patients with SMA type II or III, 156 … Continued
You live abroad and want to play a part in the Telethon? Join the Telethon for French people abroad and help us break records of mobilization around the world! On December 2 and 3, 2022, the Telethon will rally together millions of French people to support research and enable the AFM-Telethon to fulfill its missions … Continued
The international INCEPTUS study, a natural history study prior to the ASPIRO gene therapy trial to which I-Motion contributed, involved 34 children under 4 years of age with X-linked myotubular myopathy on respiratory support. During a median follow-up of 13 months (from 5 months to more than 2.5 years), there were three deaths (from inhalation … Continued
MEX-NM-301 clinical study opens at I-Motion. This open-label, non-comparative phase III study aims to evaluate the steady-state pharmacokinetics, safety, and efficacy of Mexiletine in adolescents and children with Myotonic disorders. Mexiletine is a sodium channel blocker indicated, in adult, in France, for the symptomatic treatment of myotonic syndromes (myotonic dystrophies and non-dystrophic myotonias or channelopathies). … Continued
I-Motion is recruiting patients with Duchenne muscular dystrophy to participate in two pharmacological trials designed to test an antifibrotic monoclonal antibody, pamrevlumab (or FG-3019), developed by FibroGen. The objective of these phase III trials is to assess the tolerance, safety and efficacy on the upper limbs, respiratory and cardiac functions of pamrevlumab administered by intravenous … Continued
France Pietri-Rouxel, leader of the Gene Therapy for DMD & Skeletal Muscle Pathophysiology Group at the Myology Centre for Research of the institute was the guest of Sidonie Bonnec in the radio programme “Minute Papillon” on the French radio station France Bleu on June 3. Many questions around muscle and its study were addressed: what is myology; how the … Continued
